Phoenix Biotech Acquisition Corp. (CEROW) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
201 HASKINS WAY SOUTH SAN FRANCISCO, CA 94080 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 97 | 476 | 1,099 | |||
| Cash and cash equivalent | 97 | 476 | 1,099 | |||
| Asset, held-in-trust | 8,436 | 41,666 | ||||
| Other undisclosed current assets | 225 | 263 | ||||
| Total current assets: | 8,533 | 42,367 | 1,361 | |||
| Noncurrent Assets | ||||||
| Operating lease, right-of-use asset | ||||||
| Property, plant and equipment | ||||||
| Prepaid expense | 201 | |||||
| Asset, held-in-trust | 23 | 178,500 | ||||
| Deferred costs | ||||||
| Other undisclosed noncurrent assets | 17 | |||||
| Total noncurrent assets: | 23 | 178,717 | ||||
| Other undisclosed assets | 4 | |||||
| TOTAL ASSETS: | 8,561 | 42,367 | 180,078 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities, including: | 3,535 | 1,653 | 14 | |||
| Accounts payable | ||||||
| Accrued liabilities | 24 | 599 | ||||
| Other undisclosed accounts payable and accrued liabilities | 3,511 | 1,054 | 14 | |||
| Debt | ||||||
| Due to related parties | ✕ | ✕ | 653 | 3 | ||
| Other undisclosed current liabilities | 1,638 | 28,442 | 80 | |||
| Total current liabilities: | 5,173 | 30,748 | 98 | |||
| Noncurrent Liabilities | ||||||
| Liabilities, other than long-term debt | 9,150 | |||||
| Deferred revenue | 9,150 | |||||
| Operating lease, liability | ||||||
| Other undisclosed noncurrent liabilities | 9,150 | 9,150 | ||||
| Total noncurrent liabilities: | 9,150 | 9,150 | 9,150 | |||
| Total liabilities: | 14,323 | 39,898 | 9,248 | |||
| Temporary equity, including noncontrolling interest | 8,436 | 13,224 | 178,500 | |||
| Equity | ||||||
| Equity, attributable to parent, including: | (14,199) | (10,755) | (7,670) | |||
| Additional paid in capital | ||||||
| Accumulated deficit | (14,200) | |||||
| Stockholders' equity note, subscriptions receivable | ||||||
| Other undisclosed equity, attributable to parent | 1 | (10,755) | (7,670) | |||
| Total equity: | (14,199) | (10,755) | (7,670) | |||
| TOTAL LIABILITIES AND EQUITY: | 8,561 | 42,367 | 180,078 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|
| Revenues (Other Income) | |||||
| Gross profit: | |||||
| Operating expenses | (2,933) | (2,905) | |||
| Other undisclosed operating loss | |||||
| Operating loss: | (2,933) | (2,905) | |||
| Nonoperating income | 492 | 2,837 | |||
| Investment income, nonoperating | 2,837 | ||||
| Other nonoperating income | 492 | ||||
| Interest and debt expense | |||||
| Loss from continuing operations before income taxes: | (2,441) | (69) | |||
| Income tax expense | (95) | (599) | |||
| Net loss: | (2,536) | (668) | |||
| Other undisclosed net income attributable to parent | |||||
| Net loss attributable to parent: | (2,536) | (668) | |||
| Preferred stock dividends and other adjustments | (606) | ||||
| Net loss available to common stockholders, diluted: | (3,143) | (668) | |||
Comprehensive Income ($ in thousands)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|
| Net loss: | (2,536) | (668) | |||
| Comprehensive loss, net of tax, attributable to parent: | (2,536) | (668) | |||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.